Segerer S, Bogner J R, Walli R, Loch O, Goebel F D
Infektionsabteilung, Universität München, Germany.
Infection. 1999 Mar-Apr;27(2):77-81. doi: 10.1007/BF02560501.
To define the extent and time course of HIV-proteinase inhibitor (PI) effects on serum lipid levels 148 patients on triple combination therapy including PIs and 91 patients on therapy with two nucleosides as a control group were evaluated. In the PI group there was a significant increase in total cholesterol after 3, 6 and 12 months compared to the baseline level (198, 204 and 203 vs. 176 mg/dl). The increase in triglycerides was 25.5% from the baseline at month 3. Indinavir had a significantly higher impact on cholesterol levels than saquinavir. No changes in lipids were seen in the control group. It was concluded that hyperlipidemia is associated with PI use, becomes evident within 3 months of treatment and seems to be substance specific.
为明确人类免疫缺陷病毒蛋白酶抑制剂（PI）对血清脂质水平的影响程度及时间进程，对148例接受含PI的三联联合治疗的患者和91例接受两种核苷治疗作为对照组的患者进行了评估。与基线水平相比，PI组在3、6和12个月时总胆固醇显著升高（分别为198、204和203 vs. 176mg/dl）。甘油三酯在第3个月时较基线水平升高了25.5%。茚地那韦对胆固醇水平的影响显著高于沙奎那韦。对照组脂质未见变化。得出的结论是，高脂血症与使用PI有关，在治疗3个月内变得明显，且似乎具有药物特异性。
